Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 3/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698855 | 0.85 | KEAP1 (0.70) | KEAP1ALDH1A1SMN1; SMN2POLBKIF11 | |
| SCHEMBL26386062 | 0.81 | HPGD (0.47) | ALDH1A1SMN1; SMN2BRD4HTTNR3C2 | |
| SCHEMBL26386065 | 0.79 | KDM1A (0.48) | SMN1; SMN2BRD4KDM1A | |
| SCHEMBL27183105 | 0.78 | CA2 (0.45) | ALDH1A1SMN1; SMN2HSD17B2 | |
| SCHEMBL9307018 | 0.78 | KEAP1 (0.59) | KEAP1ALDH1A1SMN1; SMN2POLBKIF11 | |
| SCHEMBL1488105 | 0.78 | KEAP1 (0.59) | KEAP1ALDH1A1SMN1; SMN2POLBKIF11 | |
| SCHEMBL9865360 | 0.78 | KEAP1 (0.59) | KEAP1ALDH1A1SMN1; SMN2POLBKIF11 | |
| SCHEMBL169803 | 0.78 | KEAP1 (0.59) | KEAP1ALDH1A1SMN1; SMN2POLBKIF11 | |
| SCHEMBL31216162 | 0.77 | KEAP1 (0.53) | KEAP1ALDH1A1SMN1; SMN2POLBKIF11 | |
| SCHEMBL5262193 | 0.77 | NR3C1 (0.56) | KEAP1ALDH1A1SMN1; SMN2POLBKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228502-A1 | 2-PHENYLAMINO PYRROLOPYRIMIDINES AS ACK1 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-11 | — | — | US | disclosed |
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023192901-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2022226290-A1 | 2-PHENYLAMINO PYRROLOPYRIMIDINES AS ACK1 INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| EP-3052501-B1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2022-06-22 | — | — | EP | disclosed |
| EP-3429994-B1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LTD (GB) | 2021-06-16 | — | — | EP | disclosed |
| EP-3733670-A1 | TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Mediconns (Shanghai) Biopharmaceutical Co., Ltd (CN) | 2020-11-04 | — | — | EP | disclosed |
| US-10544149-B2 | Bicyclic alkyne derivatives and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-01-28 | — | — | US | disclosed |
| US-20180194771-A1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-07-12 | — | — | US | disclosed |
| US-9884867-B2 | Bicyclic alkyne derivatives and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-06 | — | — | US | disclosed |
| US-5891883-A | 4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-06 | — | — | US | disclosed |
| EP-0828493-A4 | 4.4-(DISUBSTITUTED)CYCLOHEXAN-1-OLS-MONOMERS AND RELATED COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 1998-09-02 | — | — | EP | disclosed |
| CN-1192146-A | 4, 4-disubstituted cyclohexan-1-ol monomers and related compounds | SMITHKLINE BEECHAM CORP (US) | 1998-09-02 | — | — | CN | disclosed |
| EP-0794774-A4 | 4,4-(DISUBSTITUTED)CYCLOHEXAN-1-OLS MONOMERS AND RELATED COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 1998-04-29 | — | — | EP | disclosed |
| EP-0828493-A1 | 4.4-(DISUBSTITUTED)CYCLOHEXAN-1-OLS-MONOMERS AND RELATED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-03-18 | — | — | EP | disclosed |
| CN-1175242-A | 3, 3 -(disubstituted) cyclohexan -1 -one monomers and related compounds | SMITHKLINE BEECHAM CORP (US) | 1998-03-04 | — | — | CN | disclosed |
| CN-1175210-A | 4, 4 -(disubstituted) cyclohexan -1 -ols and related compounds | SMITHKLINE BEECHAM CORP (US) | 1998-03-04 | — | — | CN | disclosed |
| EP-0794774-A1 | 4,4-(DISUBSTITUTED)CYCLOHEXAN-1-OLS MONOMERS AND RELATED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996038150-A1 | 4.4-(DISUBSTITUTED)CYCLOHEXAN-1-OLS-MONOMERS AND RELATED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1996019988-A1 | 4,4-(DISUBSTITUTED)CYCLOHEXAN-1-OLS MONOMERS AND RELATED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228502-A1 | 2-PHENYLAMINO PYRROLOPYRIMIDINES AS ACK1 INHIBITORS | ADCK1, DCK, TNKS2 | KEAP1 2235/4885ALDH1A1 2860/4885SMN1; SMN2 1149/4885 |
| US-10544149-B2 | Bicyclic alkyne derivatives and uses thereof | MAPKAPK2, MAP4K2, MKNK2 | KEAP1 1489/4885ALDH1A1 2664/4885SMN1; SMN2 567/4885 |
| US-20180194771-A1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | MAPKAPK2, CAMKK2, MKNK2 | KEAP1 1394/4885ALDH1A1 2703/4885SMN1; SMN2 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.